










IN THE CLAIMS:


35. A compound selected from the group consisting of:






or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof.

36. (New) A compound having the structure:




or a pharmaceutical acceptable salt, enantiomer, stereoisomer, solvate or polymorph thereof.

37. (New) A compound having the structure:




or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate or polymorph thereof.

38. (New) A compound having the structure:



or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate or polymorph thereof.

39. (New) A compound having the structure:



or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate or polymorph thereof.

40. (New) A pharmaceutical composition comprising a compound of claim 35, and a pharmaceutically acceptable carrier.